[1]

Snigdha K, Gangwani KS, Lapalikar GV, et al. Hippo signaling in cancer: lessons from Drosophila models[J/OL]. Front Cell Dev Biol, 2019, 7: 85[2022-04-01]. https://www.frontiersin.org/articles/10.3389/fcell.2019.00085/full. DOI: 10.3389/fcell.2019.00085.
[2] Ma SH, Meng ZP, Chen R, et al.  The Hippo pathway: biology and pathophysiology[J]. Annu Rev Biochem, 2019, 88: 577-604.   doi: 10.1146/annurev-biochem-013118-111829
[3] Wei YJ, Yee PP, Liu ZJ, et al.  NEDD4L-Mediated merlin ubiquitination facilitates Hippo pathway activation[J]. EMBO Rep, 2020, 21(12): e50642-.   doi: 10.15252/embr.202050642
[4] Ling C, Zheng YG, Yin F, et al.  The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to expanded[J]. Proc Natl Acad Sci USA, 2010, 107(23): 10532-10537.   doi: 10.1073/pnas.1004279107
[5] Hong AW, Meng ZP, Guan KL.  The Hippo pathway in intestinal regeneration and disease[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(6): 324-337.   doi: 10.1038/nrgastro.2016.59
[6]

Meng ZP, Moroishi T, Mottier-Pavie V, et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway[J/OL]. Nat Commun, 2015, 6: 8357[2022-04-01]. https://www.nature.com/articles/ncomms9357. DOI: 10.1038/ncomms9357.
[7]

Qi YF, Yu J, Han W, et al. A splicing isoform of TEAD4 attenuates the Hippo-YAP signalling to inhibit tumour proliferation[J/OL]. Nat Commun, 2016, 7: ncomms11840[2022-04-01]. https://www.nature.com/articles/ncomms11840. DOI: 10.1038/ncomms11840.
[8]

Emami SS, Zhang D, Yang XL. Interaction of the Hippo pathway and phosphatases in tumorigenesis[J/OL]. Cancers (Basel), 2020, 12(9): 2438[2022-04-01]. https://www.mdpi.com/2072-6694/12/9/2438. DOI: 10.3390/cancers12092438.
[9] van Rensburg HJJ, Azad T, Ling M, et al.  The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1[J]. Cancer Res, 2018, 78(6): 1457-1470.   doi: 10.1158/0008-5472.CAN-17-3139
[10] Passaniti A, Brusgard JL, Qiao YT, et al.  Roles of RUNX in Hippo pathway signaling[J]. Adv Exp Med Biol, 2017, 962: 435-448.   doi: 10.1007/978-981-10-3233-2_26
[11]

Zhou XX, Chen N, Xu HZ, et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma[J/OL]. J Hematol Oncol, 2020, 13(1): 77[2022-04-01]. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00906-1. DOI: 10.1186/s13045-020-00906-1.
[12] Wang GF, Liu XM, Xie JL, et al.  PDK-1 mediated Hippo-YAP-IRS2 signaling pathway and involved in the apoptosis of non-small cell lung cancer cells[J]. Biosci Rep, 2019, 39(5): BSR20182099-.   doi: 10.1042/BSR20182099
[13] Sun YB, Jiang TX, Jia YQ, et al.  LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway[J]. Cell Cycle, 2019, 18(19): 2509-2523.   doi: 10.1080/15384101.2019.1652034
[14] Guo PD, Lu XX, Gan WJ, et al.  RARγ downregulation contributes to colorectal tumorigenesis and metastasis by derepressing the Hippo-Yap pathway[J]. Cancer Res, 2016, 76(13): 3813-3825.   doi: 10.1158/0008-5472.CAN-15-2882
[15] Xu JX, Fang XJ, Long LY, et al.  HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway[J]. Cancer Biol Ther, 2021, 22(1): 5-11.   doi: 10.1080/15384047.2020.1832429
[16] Dey A, Varelas X, Guan KL.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine[J]. Nat Rev Drug Discov, 2020, 19(7): 480-494.   doi: 10.1038/s41573-020-0070-z
[17] Lin LP, Sabnis AJ, Chan E, et al.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies[J]. Nat Genet, 2015, 47(3): 250-256.   doi: 10.1038/ng.3218
[18] Wang H, Tang J, Su ZW.  YAP confers resistance to vandetanib in medullary thyroid cancer[J]. Biochem Cell Biol, 2020, 98(3): 443-448.   doi: 10.1139/bcb-2019-0354
[19] Jin X, Zhu LH, Xiao S, et al.  MST1 inhibits the progression of breast cancer by regulating the Hippo signaling pathway and may serve as a prognostic biomarker[J]. Mol Med Rep, 2021, 23(5): 383-.   doi: 10.3892/mmr.2021.12022
[20] Hu YL, Wang B, Wang L, et al.  Mammalian STE20-like kinase 1 regulates pancreatic cancer cell survival and migration through Mfn2-mediated mitophagy[J]. Mol Med Rep, 2020, 22(1): 398-404.   doi: 10.3892/mmr.2020.11098
[21]

Wang LX, Lin M, Chu M, et al. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression[J/OL]. EBioMedicine, 2020, 56: 102795[2022-04-01]. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30170-5/fulltext. DOI: 10.1016/j.ebiom.2020.102795.
[22] Luo SY, Kwok HH, Yang PC, et al.  Expression of large tumour suppressor (LATS) kinases modulates chemotherapy response in advanced non-small cell lung cancer[J]. Transl Lung Cancer Res, 2020, 9(2): 294-305.   doi: 10.21037/tlcr.2020.03.26
[23] Quan M, Chen ZQ, Jiao F, et al.  Lysine demethylase 2 (KDM2B) regulates Hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression[J]. J Exp Clin Cancer Res, 2020, 39(1): 13-.   doi: 10.1186/s13046-019-1489-0
[24] Zagurovskaya M, Shareef MM, Das A, et al.  EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells[J]. Oncogene, 2009, 28(8): 1121-1131.   doi: 10.1038/onc.2008.461
[25]

Xu XF, Chen Y, Wang X, et al. Role of Hippo/YAP signaling in irradiation-induced glioma cell apoptosis[J/OL]. Cancer Manag Res, 2019, 11: 7577−7585[2022-04-01]. https://www.dovepress.com/role-of-hippoyap-signaling-in-irradiation-induced-glioma-cell-apoptosi-peer-reviewed-fulltext-article-CMAR. DOI: 10.2147/CMAR.S210825.
[26] Gopal U, Mowery Y, Young K, et al.  Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling[J]. J Biol Chem, 2019, 294(38): 13939-13952.   doi: 10.1074/jbc.RA119.009091
[27]

Zhang LR, Shi H, Chen HB, et al. Dedifferentiation process driven by radiotherapy-induced HMGB1/TLR2/YAP/HIF-1α signaling enhances pancreatic cancer stemness[J/OL]. Cell Death Dis, 2019, 10(10): 724[2022-04-01]. https://www.nature.com/articles/s41419-019-1956-8. DOI: 10.1038/s41419-019-1956-8.
[28]

Zhou W, Liu MY, Li X, et al. Arsenic Nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy[J/OL]. Cell Biosci, 2020, 10(1): 146[2022-04-01]. https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-020-00508-x. DOI: 10.1186/s13578-020-00508-x.
[29] Pathak S, Banerjee A, Meng WJ, et al.  Significant expression of tafazzin (TAZ) protein in colon cancer cells and its downregulation by radiation[J]. Int J Radiat Biol, 2018, 94(1): 79-87.   doi: 10.1080/09553002.2018.1400191
[30]

Lee S, Kang H, Shin E, et al. BEX1 and BEX4 induce GBM progression through regulation of actin polymerization and activation of YAP/TAZ signaling[J/OL]. Int J Mol Sci, 2021, 22(18): 9845[2022-04-01]. https://www.mdpi.com/1422-0067/22/18/9845. DOI: 10.3390/ijms22189845.
[31] Zhang Y, Wang Y, Zhou D, et al.  Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair[J]. Oncogene, 2021, 40(27): 4580-4591.   doi: 10.1038/s41388-021-01878-3
[32] Li ZL, Liu XJ, Yu HZ, et al.  USP21 regulates Hippo signaling to promote radioresistance by deubiquitinating FOXM1 in cervical cancer[J]. Hum Cell, 2022, 35(1): 333-347.   doi: 10.1007/s13577-021-00650-9
[33]

Li YX, Sun C, Tan YG, et al. ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal transition[J/OL]. Int J Biol Sci, 2021, 17(2): 635−650[2022-04-01]. https://www.ijbs.com/v17p0635.htm. DOI: 10.7150/ijbs.52319.
[34] Zeng YL, Liu Q, Wang Y, et al.  CDK5 activates Hippo signaling to confer resistance to radiation therapy via upregulating TAZ in lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3): 758-769.   doi: 10.1016/j.ijrobp.2020.05.005
[35]

Tsujiura M, Mazack V, Sudol M, et al. Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer[J/OL]. PLoS One, 2014, 9(6): e100974[2022-04-01]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100974. DOI: 10.1371/journal.pone.0100974.
[36] Fernandez-L A, Squatrito M, Northcott P, et al.  Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation[J]. Oncogene, 2012, 31(15): 1923-1937.   doi: 10.1038/onc.2011.379
[37]

Li L, Wang N, Zhu MZ, et al. Aberrant super-enhancer-driven oncogene ENC1 promotes the radio-resistance of breast carcinoma[J/OL]. Cell Death Dis, 2021, 12(8): 777[2022-04-01]. https://www.nature.com/articles/s41419-021-04060-5. DOI: 10.1038/s41419-021-04060-5.
[38] Li F, Xu Y, Liu B, et al.  YAP1-mediated CDK6 activation confers radiation resistance in esophageal cancer − rationale for the combination of YAP1 and CDK4/6 inhibitors in esophageal cancer[J]. Clin Cancer Res, 2019, 25(7): 2264-2277.   doi: 10.1158/1078-0432.CCR-18-1029
[39]

Yao Q, Yang J, Liu T, et al. Long noncoding RNA MALAT1 promotes the stemness of esophageal squamous cell carcinoma by enhancing YAP transcriptional activity[J/OL]. FEBS Open Bio, 2019, 9(8): 1392−1402[2022-04-01]. https://febs.onlinelibrary.wiley.com/doi/10.1002/2211-5463.12676. DOI: 10.1002/2211-5463.12676.
[40] Zhou W, Zhang L, Chen PX, et al.  Thymine DNA glycosylase-regulated TAZ promotes radioresistance by targeting nonhomologous end joining and tumor progression in esophageal cancer[J]. Cancer Sci, 2020, 111(10): 3613-3625.   doi: 10.1111/cas.14622
[41] White SM, Murakami S, Yi CL.  The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity[J]. Oncogene, 2019, 38(16): 2899-2909.   doi: 10.1038/s41388-018-0649-6